Literature DB >> 28543047

Less overdiagnosis of kidney cancer? an age-period-cohort analysis of incidence trends in 16 populations worldwide.

Ariana Znaor1, Mathieu Laversanne1, Freddie Bray1.   

Abstract

The increasing rates of kidney cancer incidence, reported in many populations globally, have been attributed both to increasing exposures to environmental risk factors, as well as increasing levels of incidental diagnosis due to widespread use of imaging. To better understand these trends, we examine long-term cancer registry data worldwide, focusing on the roles of birth cohort and calendar period, proxies for changes in risk factor prevalence and detection practice respectively. We used an augmented version of the Cancer Incidence in Five Continents series to analyze kidney cancer incidence rates 1978-2007 in 16 geographically representative populations worldwide by sex for ages 30-74, using age-period-cohort (APC) analysis. The full APC model provided the best fit to the data in most studied populations. While kidney cancer incidence rates have been increasing in successive generations born from the early twentieth century in most countries, equivalent period-specific rises were observed from the late-1970s, although these have subsequently stabilized in certain European countries (the Czech Republic, Lithuania, Finland, Spain) as well as Japan from the mid-1990s, and from the mid-2000s, in Colombia, Costa Rica and Australia. Our results indicate that the effects of both birth cohort and calendar period contribute to the international kidney cancer incidence trends. While cohort-specific increases may partly reflect the rising trends in obesity prevalence and the need for more effective primary prevention policies, the attenuations in period-specific increases (observed in 8 of the 16 populations) highlight a possible change in imaging practices that could lead to mitigation of overdiagnosis and overtreatment.
© 2017 UICC.

Entities:  

Keywords:  age-period-cohort analysis; incidence trends; kidney cancer

Mesh:

Year:  2017        PMID: 28543047     DOI: 10.1002/ijc.30799

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  ABO blood group polymorphism has an impact on prostate, kidney and bladder cancer in association with longevity.

Authors:  Donatas Stakišaitis; Milda Juknevičienė; Albertas Ulys; Dalia Žaliūnienė; Daiva Stanislovaitienė; Ramunė Šepetienė; Anželika Slavinska; Kęstutis Sužiedėlis; Vita Lesauskaitė
Journal:  Oncol Lett       Date:  2018-05-21       Impact factor: 2.967

2.  Trends in cancer incidence in Uruguay: 2002 -2015.

Authors:  Mariela Garau; Carina Musetti; Rafael Alonso; Enrique Barrios
Journal:  Colomb Med (Cali)       Date:  2019-12-30

3.  Impact of the Discordance Between Scales of Memorial Sloan-Kettering Cancer Center and International Metastatic Renal Cell Carcinoma Database Consortium in Patients' Prognosis With Metastatic Renal Cancer.

Authors:  Hiram Josue Grimaldo-Roque; Erika Adriana Martinez-Castaneda; Mariana G Morales-Garcia; Jorge Luis Leal-Hidalgo; Valeria M Torres-Guillen; Rita Dorantes-Heredia; Daniel Motola-Kuba; Jose Manuel Ruiz-Morales
Journal:  World J Oncol       Date:  2022-04-23

4.  Dietary Patterns in Italy and the Risk of Renal Cell Carcinoma.

Authors:  Michela Dalmartello; Francesca Bravi; Diego Serraino; Anna Crispo; Monica Ferraroni; Carlo La Vecchia; Valeria Edefonti
Journal:  Nutrients       Date:  2020-01-02       Impact factor: 5.717

5.  Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Colombia: A systematic review.

Authors:  Juan-Sebastian Franco; David Vizcaya
Journal:  Pharmacol Res Perspect       Date:  2020-10

Review 6.  Epidemiology and Risk Factors for Kidney Cancer.

Authors:  Ghislaine Scelo; Tricia L Larose
Journal:  J Clin Oncol       Date:  2018-10-29       Impact factor: 44.544

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.